New IBS Drug Trial
Lubiprostone to Treat IBS-C
Takeda Pharmaceuticals North America is currently planning a phase 3 clinical trial for Lubiprostone, a drug that may treat IBS-C. More than 500 patients will be enrolled in two phase 3 trials for the drug.
Takeda Pharmaceuticals North America is currently planning a phase 3 clinical trial for Lubiprostone, a drug that may treat IBS-C. More than 500 patients will be enrolled in two phase 3 trials for the drug.
Wednesday May 18, 2005 | comments (0)
Display Latest Headlines | 
| 
| Read Archives
powered by WordPress